ALKEM2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2020-04-01 2021-03-31 2021-01-27 INR Millions Third quarter Single segment The Company is exclusively engaged in pharmaceutical business 2020-10-01 2020-12-31 Unaudited Standalone 17787500000.00 724600000.00 18512100000.00 6119900000.00 2448400000.00 -2073600000.00 2882000000.00 87700000.00 500800000.00 3979100000.00 13944300000.00 4567800000.00 0.00 4567800000.00 800700000.00 -242700000.00 558000000.00 0.00 4009800000.00 0.00 0.00 0.00 0.00 4009800000.00 -2300000.00 4007500000.00 0.00 0.00 239100000.00 2 33.54 33.54 0.00 0.00 33.54 33.54 1. The above unaudited standalone financial results were reviewed and recommended by the Audit Committee on 4 February 2021 and subsequently approved by the Board of Directors at its meeting held on 5 February 2021. The figures for the quarter and nine months ended 31 December 2020 have been subjected to limited review by the statutory auditors. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2020. n n2. During the quarter ended 31 December 2020, the Company has received net consideration of Rs.351.0 Million towards assignment of a trademark together with associated goodwill, business and commercial rights and the same has been recognised under Other Income. n n3. The Code on Social Security, 2020 ('Code') received Presidential assent in September 2020 and the same has been published in the Gazette of India. However, the related final rules and the date on which the Code will come into effect has not been notified. The Company will assess the impact once the subject rules are notified and will give appropriate impact in its financial statements in the period in which the Code becomes effective. n n4. The Board of Directors at its meeting held on 5 February 2021 have declared an interim dividend of Rs 25 (Rupees Twenty five only) per equity share (1250% on the face value of Rs 2 each) for the financial year ended 2020-21. n n5. The Company has considered internal and external information while assessing recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions. n n6. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. n n7. Previous periods' figures have been regrouped/reclassified, where necessary, to make them comparable with the figures for the current period. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 53022100000.00 1412400000.00 54434500000.00 14699300000.00 7124000000.00 -2812100000.00 8677600000.00 355700000.00 1495500000.00 10008100000.00 39548100000.00 14886400000.00 0.00 14886400000.00 2608900000.00 -945900000.00 1663000000.00 0.00 13223400000.00 0.00 0.00 0.00 0.00 13223400000.00 -7100000.00 13216300000.00 0.00 0.00 239100000.00 2 110.60 110.60 0.00 0.00 110.60 110.60 Other expenses 3979100000.00 Other expenses 10008100000.00